RELAPSED NON HODGKIN LYMPHOMA
Clinical trials for RELAPSED NON HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED NON HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for RELAPSED NON HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New cell addback aims to slash infection risk in child stem cell recipients
Disease control Recruiting nowThis study tests whether adding a specific type of immune cell (memory T cells) after a stem cell transplant can help prevent serious viral and fungal infections. About 100 children and young adults with blood cancers, immune disorders, or bone marrow failure will receive this ex…
Matched conditions: RELAPSED NON HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Children's Hospital of Philadelphia • Aim: Disease control
Last updated May 26, 2026 05:53 UTC
-
New Dual-Targeting CAR t therapy aims to outperform standard treatment for blood cancer
Disease control Recruiting nowThis Phase 3 trial tests a new CAR T-cell therapy called ronde-cel, which targets two proteins (CD19 and CD20) on lymphoma cells, against the standard single-target CAR T therapy. The study involves 400 adults with large B-cell lymphoma that has returned or not responded after in…
Matched conditions: RELAPSED NON HODGKIN LYMPHOMA
Phase: PHASE3 • Sponsor: Lyell Immunopharma, Inc. • Aim: Disease control
Last updated May 26, 2026 05:53 UTC
-
Promising combo targets Hard-to-Treat lymphomas
Disease control Recruiting nowThis study tests a combination of two drugs—pembrolizumab and all-trans retinoic acid (ATRA)—in adults with relapsed or refractory Hodgkin lymphoma or B-Non-Hodgkin lymphoma. The goal is to see if the combo is safe and helps shrink tumors. About 24 participants will receive the t…
Matched conditions: RELAPSED NON HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Rita Assi • Aim: Disease control
Last updated May 26, 2026 05:50 UTC
-
Double-Barreled CAR t cells take on tough lymphomas
Disease control Recruiting nowThis early-phase study tests a new type of CAR T cell therapy that targets two proteins (CD79b and CD19) on lymphoma cells. It is for people with non-Hodgkin lymphoma that has come back or not responded to standard treatments. The main goals are to check safety and find the right…
Matched conditions: RELAPSED NON HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: Marcela V. Maus, M.D.,Ph.D. • Aim: Disease control
Last updated May 26, 2026 05:48 UTC
-
New CAR T-Cell therapy targets tough lymphoma cancers
Disease control Recruiting nowThis early-phase study tests a new treatment called SynKIR-310 for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior therapies. The treatment uses a patient's own immune cells, modified to recognize and attack cancer cells. The main…
Matched conditions: RELAPSED NON HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: Verismo Therapeutics • Aim: Disease control
Last updated May 26, 2026 05:47 UTC
-
Radiation boost before CAR-T may zap stubborn lymphoma tumors
Disease control Recruiting nowThis study tests whether giving targeted radiation to large tumors before CAR-T cell therapy can help control cancer better in people with aggressive large B-cell lymphoma. About 27 participants with bulky disease (tumors at least 5 cm) will receive this combination. The goal is …
Matched conditions: RELAPSED NON HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated May 26, 2026 05:45 UTC
-
New drug aims to tame CAR-T Therapy's dangerous side effects
Disease control Recruiting nowThis study tests whether the drug emapalumab can prevent severe cytokine release syndrome (CRS), a common and serious side effect of CAR-T cell therapy, in adults with certain types of non-Hodgkin lymphoma that have come back or not responded to treatment. About 28 participants w…
Matched conditions: RELAPSED NON HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Marcela V. Maus, M.D.,Ph.D. • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
Double-Target attack: new CAR t therapy takes on tough lymphoma
Disease control Recruiting nowThis study tests a new treatment called ronde-cel for people with aggressive B-cell lymphoma that has come back or not improved after at least two prior therapies. The treatment uses a patient's own immune cells, modified to target two different markers on cancer cells. The goal …
Matched conditions: RELAPSED NON HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Lyell Immunopharma, Inc. • Aim: Disease control
Last updated May 22, 2026 13:52 UTC
-
New CAR T-Cell trial offers hope for Tough-to-Treat blood cancers
Disease control Recruiting nowThis study tests a personalized treatment using a patient's own immune cells, modified to attack cancer. It is for people with relapsed aggressive lymphoma or acute lymphoblastic leukemia (ALL) who have not responded to standard therapies. The approach aims to control the disease…
Matched conditions: RELAPSED NON HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: University of Alberta • Aim: Disease control
Last updated May 19, 2026 12:01 UTC
-
New combo attack on hard-to-treat lymphoma shows promise in early trial
Disease control Recruiting nowThis study tests whether giving a special immune cell treatment (CAR-T therapy) followed by two additional drugs (mosunetuzumab and polatuzumab) can shrink tumors in people with aggressive non-Hodgkin lymphoma that has returned or not responded to prior treatments. About 22 adult…
Matched conditions: RELAPSED NON HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Lazaros Lekakis • Aim: Disease control
Last updated May 14, 2026 12:06 UTC